Upadacitinib Safety Record Extends to 7 Years in Pooled Analysis
Pooled analysis findings reported by HCPLive support upadacitinib's safety in atopic dermatitis over up to 7 years of follow-up, extending the oral JAK inhibitor's long-term evidence base.